Lord, Abbett & Co. LLC
- SEC CIK
- 0000728100
- Latest filing
- Aug 14, 2026
XENE holding history
Xenon Pharmaceuticals Inc. in every 13F filed by Lord, Abbett & Co. LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
XENE overviewAll 13F holders of XENEFull Q2 2026 holdings
- Shares (Q2 2025)
- 0
- Sold out in Q2 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2025 | 0 | $0 | 0.0% | −87,981−100.0% | Sold out | Holders |
| Q1 2025 | 87,981 | $2.95M | <0.1% | −106,990−54.9% | Reduced | Holders |
| Q4 2024 | 194,971 | $7.64M | <0.1% | +20,986+12.1% | Added | Holders |
| Q3 2024 | 173,985 | $6.85M | <0.1% | −16,048−8.4% | Reduced | Holders |
| Q2 2024 | 190,033 | $7.41M | <0.1% | −705,163−78.8% | Reduced | Holders |
| Q1 2024 | 895,196 | $38.5M | 0.1% | +177,224+24.7% | Added | Holders |
| Q4 2023 | 717,972 | $33.1M | 0.1% | −431,196−37.5% | Reduced | Holders |
| Q3 2023 | 1,149,168 | $39.3M | 0.1% | −809,372−41.3% | Reduced | Holders |
| Q2 2023 | 1,958,540 | $75.4M | 0.3% | +175,929+9.9% | Added | Holders |
| Q1 2023 | 1,782,611 | $63.8M | 0.2% | −341,398−16.1% | Reduced | Holders |
| Q4 2022 | 2,124,009 | $83.7M | 0.3% | +210,148+11.0% | Added | Holders |
| Q3 2022 | 1,913,861 | $69.1M | 0.3% | +56,265+3.0% | Added | Holders |
| Q2 2022 | 1,857,596 | $56.5M | 0.2% | +66,853+3.7% | Added | Holders |
| Q1 2022 | 1,790,743 | $54.7M | 0.1% | −4,337−0.2% | Reduced | Holders |
| Q4 2021 | 1,795,080 | $56.1M | 0.1% | +1,416,722+374.4% | Added | Holders |
| Q3 2021 | 378,358 | $5.78M | <0.1% | −6,367−1.7% | Reduced | Holders |
| Q2 2021 | 384,725 | $7.16M | <0.1% | −33,825−8.1% | Reduced | Holders |
| Q1 2021 | 418,550 | $7.49M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.